KCNQ2 Encephalopathy and Responsiveness to Pyridoxal-5'-Phosphate

Area of Science:

• Neurogenetics
• Epilepsy Research
• Developmental Neuroscience

Background:

• KCNQ2 mutations are associated with a spectrum of epileptic encephalopathies, from benign familial neonatal seizures to severe early-onset forms.
• Neonatal epileptic encephalopathy presents significant challenges in diagnosis and treatment, often requiring multi-drug approaches.

Observation:

• A case of KCNQ2 encephalopathy presented with neonatal seizures, initially refractory to standard anticonvulsants.
• EEG monitoring revealed persistent epileptiform discharges despite intravenous pyridoxine administration.
• Seizures recurred and showed limited response to oral pyridoxine but dramatic improvement with oral pyridoxal-5'-phosphate (PLP).

Findings:

• Pyridoxal-5'-phosphate (PLP) demonstrated significant efficacy in controlling seizures in an infant with KCNQ2 encephalopathy.
• This case highlights the potential differential response to vitamin B6 forms (pyridoxine vs. PLP) in KCNQ2-related epilepsy.

Implications:

• Clinicians should consider trials of both intravenous and oral pyridoxine, followed by oral PLP, in infants with neonatal epileptic encephalopathy and known KCNQ2 mutations.
• KCNQ2 mutations should be considered in the differential diagnosis of vitamin B6-responsive epilepsies.
• Further research into the precise mechanisms of vitamin B6 metabolism and efficacy in KCNQ2 encephalopathy is warranted.